Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: